Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
7 search results for:

Mycosis fungoides 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 08-01-2019 | Cutaneous T-cell lymphoma | Brief review | Article

    Emerging therapies for cutaneous T-cell lymphoma

    Clinical presentation of a) mycosis fungoides and b) Sézary Syndrome. 

    Author:
    Dawn Queen, Adriana Lopez, Larisa J Geskin
  2. 13-08-2018 | FDA | News | Article
    approvalsWatch

    Mogamulizumab-kpkc approved for rare NHL subtypes

    medwireNews : A monoclonal antibody agent targeting the C-C chemokine receptor 4 may now be used for US patients with relapsed or refractory Sézary syndrome or mycosis fungoides.

  3. 22-08-2018 | Non-Hodgkin lymphoma | News | Article

    Mogamulizumab improves cutaneous T-cell lymphoma outcomes

    MAVORIC trial results support the use of the C-C chemokine receptor 4-targeted antibody mogamulizumab over the standard of care vorinostat in previously treated patients with mycosis fungoides or Sézary syndrome.

    Published in:
    Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30379-6 Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30449-2
  4. 15-11-2017 | FDA | News | Article
    approvalsWatch

    FDA approvals granted for brentuximab, letermovir

    The regular FDA approval follows results from the phase III ALCANZA study showing improved rates of objective response, complete response and progression-free survival with brentuximab vedotin for pcALCL or mycosis fungoides compared with methotrexate or bexarotene. --- The CMV DNA terminase complete inhibitor letermovir has been given Breakthrough Therapy and Orphan Drug designations for the treatment of HSCT patients who have been exposed to CMV.

  5. 02-02-2018 | Cutaneous T-cell lymphoma | Highlight | Teaser
    Expert opinion

    Emerging therapies for cutaneous T-cell lymphoma

    Cutaneous T-cell lymphomas are a heterogeneous group of T-lymphocyte malignancies with only one potentially curative treatment option that has limited applicability. Dawn Queen, Adriana Lopez, and Larisa Geskin (Columbia University Medical Center, USA) explore the most promising emerging alternative treatment options. 

  6. 09-03-2017 | Lymphoma | Case report | Article

    Cutaneous T-cell lymphoma

    She was diagnosed with mycosis fungoides (cutaneous patches and plaques) 4 years ago per skin biopsy.

    Author:
    Belen Rubio Gonzalez, Steven T Rosen, Christiane Querfeld
  7. 03-11-2015 | Hematologic cancers | Article

    Novel immunotherapies in lymphoid malignancies

    In a recent phase I study of nivolumab (Table 3), 31 patients with B-cell lymphoma were included. 145 Among 29 patients, excluding two patients with PMBL, eight patients (28%) had an objective response, including three patients with a CR and five patients with a PR. 145 The response rate was highest in patients with FL, in whom the ORR was 40%. 145 Patients with DLBCL had an ORR of 36%, including two patients with a CR and two patients with a PR. 145 This study also included patients with T-cell lymphoma ( n = 23), including 13 patients with mycosis fungoides and five patients with peripheral T-cell lymphoma (PTCL). 145 The ORR for these patients was 17%, with four patients (17%) achieving a PR—two patients with mycosis fungoides and two with PTCL. 145 A phase I study of pembrolizumab in patients with NHL is currently ongoing (NCT01953692). 146, 147 Table 3: Clinical efficacy of immune-checkpoint inhibitors Table 3 Hodgkin lymphoma Phase I studies of both nivolumab and pembrolizumab have demonstrated exciting results in patients with HL (Table 3).

    Author:
    Connie Lee Batlevi, Eri Matsuki, Renier J. Brentjens, Anas Younes
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.